In this study, we evaluated the combined effects of MCC950 and PTX on MDA-MB-231 cells, compared with MCF-12 A cells, considering that MCC950 is the most specific and efficient inhibitor of NLRP3 which alter the NLRP3 inflammasome conformation by binding the NACHT domain and implicitly affecting the associated inflammatory responses24 and the PTX`s cytotoxic effects on breast tumor cells, being a first-line chemotherapy drug used in clinical practices25. Here, NLRP3 is linked to breast neoplasm.